Romania Pharmaceuticals and Healthcare Report Q2 2015

Business Monitor International
February 25, 2015
110 Pages - SKU: BMI5475757
The US Market for Rx to OTC Switches, 7th Edition
2/2/2015 | published by: Kalorama Information
The US Market for Rx to OTC Switches Over the past 38 years the U.S. Rx-to-OTC market has grown into a $7.8 billion market. This has mainly been due to factors such as patent  |  read more...
USD 3,995
Acute Heart Failure-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
Acute Heart Failure-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 DelveInsight’s, “Acute Heart Failure-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed  |  read more...
USD 2,000
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 DelveInsight’s, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive  |  read more...
USD 2,000
Acute Upper Respiratory Tract Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
Acute Upper Respiratory Tract Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 DelveInsight’s, “Acute Upper Respiratory Tract Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III  |  read more...
USD 2,000
Dysuria-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
Dysuria-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 DelveInsight’s, “Dysuria-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Dysuria.  |  read more...
USD 2,000
Anterior Uveitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
Anterior Uveitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 DelveInsight’s, “Anterior Uveitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across  |  read more...
USD 2,000
Arthritis Pain-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
Arthritis Pain-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 DelveInsight’s, “Arthritis Pain-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across  |  read more...
USD 2,000
Ascites-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
Ascites-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 DelveInsight’s, “Ascites-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Ascites.  |  read more...
USD 2,000
Atherosclerosis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
Atherosclerosis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 DelveInsight’s, “Atherosclerosis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Atherosclerosis.  |  read more...
USD 2,000
Autism-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
Autism-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 DelveInsight’s, “Autism-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Autism.  |  read more...
USD 2,000
 

SELECT A LICENSE

    Report with 3 quarterly updates  USD 1,295  
    Report with 3 quarterly updates
3 User License
  USD 1,945  
    Report with 3 quarterly updates
5 User License
  USD 2,500  
    Report with 3 quarterly updates
Departmental/Site License
  USD 2,995  
    Global Site License Fulfilled by Publisher  USD 6,995  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!